Cheaper Medicines Act

Also known as: RA 9502 · Republic Act No. 9502 · Universally Accessible Cheaper and Quality Medicines Act of 2008 — statutory short title (Section 1) · Cheaper and Quality Medicines Act of 2008

Government

Definition

The Cheaper Medicines Act is the popular name of Republic Act No. 9502, officially “An Act Providing for Cheaper and Quality Medicines, Amending for the Purpose Republic Act No. 8293 or the Intellectual Property Code, Republic Act No. 6675 or the Generics Act of 1988, and Republic Act No. 5921 or the Pharmacy Law.” The Act was signed by President Gloria Macapagal-Arroyo on June 6, 2008, and by its Section 1 it carries the short title “Universally Accessible Cheaper and Quality Medicines Act of 2008.” Its declared policy is “to protect public health” and to ensure “access to affordable quality drugs and medicines for all,” using competition as the primary instrument and price regulation as a reserve tool, with Section 3 directing that all doubts in implementation and interpretation “be resolved in favor of protecting public health.” (LawPhil — RA 9502)

The Act works through two mechanisms. First, it rewrote the patent and access provisions of the Intellectual Property Code (RA 8293) along the lines of the flexibilities recognized in the WTO TRIPS Agreement: the patentability amendments bar patents on “the mere discovery of a new form or new property of a known substance which does not result in the enhancement of the known efficacy” (amending Sections 22 and 26); the amended Section 72.1 adopts international exhaustion, so that the patent limitation on making, using and selling applies “after a drug or medicine has been introduced in the Philippines or anywhere else in the world” — the statutory basis for parallel importation of patented medicines; the amended Section 74 expands government use of patented inventions; and a new Section 93-A creates a special compulsory license to import cheaper versions of patented drugs, immediately executory and available also for export to countries lacking manufacturing capacity. (LawPhil — RA 8293) Second, Chapter 3 of the Act built a drug price regulation mechanism: upon the recommendation of the Secretary of Health, the President may impose maximum retail prices over drugs and medicines (Section 17), backed by a DOH price-monitoring system, an Advisory Council for Medicine Price Regulation, and administrative fines of ₱50,000 to ₱5,000,000 (Sections 18–19).

Identities

Authority	Value
Wikipedia	N/A
Wikidata	N/A
DBpedia	N/A
ProductOntology	N/A
Wiktionary	N/A
Library of Congress Subject Headings	Drugs—Law and legislation
MeSH	Drug Costs
NCBI Taxonomy	N/A
AGROVOC	N/A
Google Scholar	“Universally Accessible Cheaper and Quality Medicines Act” RA 9502 Philippines drug price regulation
ConceptNet	N/A
OpenCyc	N/A

Also Known As

RA 9502
Republic Act No. 9502
Universally Accessible Cheaper and Quality Medicines Act of 2008 — statutory short title (Section 1)
Cheaper and Quality Medicines Act of 2008

Examples and Analogies

The exhaust valve analogy: before the Act, a patented medicine sold cheaply abroad could not be bought there and resold in the Philippines, because the patent still blocked the import; by adopting international exhaustion, Section 72.1 treats the patent holder’s first sale anywhere in the world as the point where Philippine patent rights over that item are exhausted — a one-time admission ticket honored wherever it was first punched.
The reserve-power analogy: price regulation under Chapter 3 operates like a brake kept in reserve — the declared preference is to let generic competition and parallel imports drive prices down, with the President’s maximum-retail-price power (Section 17) reserved for when competition fails.
Verified statutory data:
Approval: June 6, 2008, by President Gloria Macapagal-Arroyo
Short title: “Universally Accessible Cheaper and Quality Medicines Act of 2008” (Section 1)
Laws amended: RA 8293 (Intellectual Property Code), RA 6675 (Generics Act of 1988), RA 5921 (Pharmacy Law)
Patent provisions: amended Sections 22, 26, 72.1, 74, 76, 93, and added Sections 93-A, 94, 95 of RA 8293
Price provisions: Chapter 3, Sections 17–25
Effectivity: fifteen days after publication in at least two national papers of general circulation (Section 49)

Usage Scenarios

1. Parallel Importation of Patented Medicines

A government agency or any private third party may import a drug or medicine already introduced into any market in the world, because the amended Section 72.1 of the Intellectual Property Code limits patent rights once the product has been sold anywhere — the route by which cheaper legitimate stock reaches Philippine pharmacies without the patent holder’s consent.

2. Price Intervention by Executive Order

When competition is judged insufficient, the Secretary of Health recommends and the President imposes maximum retail prices over selected drugs — the pathway actually used on July 27, 2009, when Executive Order No. 821 fixed maximum drug retail prices for five molecules (amlodipine, atorvastatin, azithromycin, cytarabine, and doxorubicin) covering diseases that account for leading causes of morbidity and mortality, effective August 15, 2009, while sixteen other drugs moved to voluntary price cuts of at least fifty percent and twenty-two more to reductions of about ten to fifty percent. (LawPhil — EO 821)

3. Government Use and Compulsory Licensing

Where medicines are needed for public health programs, the amended Section 74 permits the government to use patented inventions on terms it sets, and the special compulsory license of Section 93-A authorizes importation under TRIPS — both drafted to be immediately executory, with no court except the Supreme Court able to issue a temporary restraining order or preliminary injunction against them.

4. Enforcement Against Price Manipulation

The Act penalizes price manipulation — hoarding, panic-buying creation, and overpricing among the enumerated acts — with imprisonment of five to fifteen years or fines from ₱100,000 to ₱10,000,000 (Sections 24–25), alongside the DOH’s administrative fines for violations of its orders.

5. Appeal and Protest in Price Cases

A person aggrieved by a DOH order may move for reconsideration within fifteen days or appeal to the Court of Appeals within thirty days; but certiorari in the Supreme Court does not stay the order unless the Court so directs — the provisions critics summarize as the “no protest-stops-execution” rules (Section 22).

Strategies

Use the flexibilities before the price brake: researchers trace the Act’s design as TRIPS-flexibilities first (exhaustion, government use, compulsory license) and price ceilings second, reflecting the declared policy that competition is the primary instrument.
Invoke the pro-public-health canon: Section 3’s rule that doubts are resolved in favor of protecting public health is the interpretive benchmark for the Act’s implementing rules — the drafting strategy echoing the Doha Declaration approach to TRIPS and public health.
Monitor through the Advisory Council: the DOH price-monitoring system (Section 18) and the enumerated covered drugs (Section 23) — chronic-illness medicines, vaccines, contraceptives, anesthetics, intravenous fluids, and Philippine National Drug Formulary-listed drugs — give researchers the official lenses for tracking compliance.
Build on the generics foundation: the Act consciously amends and extends the Generics Act of 1988, so students of Philippine drug policy read the two statutes as one arc — generic naming in 1988, patent and price liberalization in 2008.

Security and Safety Measures

Quality assurance as the counterpart of access: the Act’s title and policy sections couple “cheaper” with “quality,” leaving FDA registration and standards as the safety floor beneath parallel imports and generics.
Anti-circumvention of price orders: EO 821 declares that violations or circumvention of the maximum drug retail prices “shall be dealt with accordingly” and directs a DOH review of the price list three to six months after effectivity.
Judicial control concentrated in the Supreme Court: by barring lower-court injunctions against government use, compulsory licenses, and presidential price orders, the Act routes interlocutory challenges to the Supreme Court — a deliberate safeguard against delay that critics contest on due-process grounds.
Penalty gradient: administrative fines for regulatory breaches and criminal penalties for price manipulation form the enforcement ladder.

Historical Context

RA 9502 sits in the reform line that began with the Generics Act of 1988 (RA 6675), signed September 13, 1988, which mandated generic labeling and prescribing but left medicine prices largely intact — this wiki’s entry on the Generics Act of 1988 records the assessments, including the Philippine Institute for Development Studies’ question “How Effective Has the Generics Act Been?”, that documented persistently high prices and brand preference. (LawPhil — RA 6675) By the 2000s the twin pressures of the WTO TRIPS Agreement’s patent rules and Philippine price surveys pushed Congress toward a statute combining IP flexibilities with a price mechanism.

After the Act’s signing on June 6, 2008, implementation fell to the DOH and, for the patent provisions, to the Intellectual Property Office; the decisive exercise of Chapter 3 came on July 27, 2009 with EO 821, whose five-molecule maximum drug retail price list took effect August 15, 2009, with voluntary price-reduction commitments fully implemented by September 15, 2009. Later policy — the value-added tax exemption on selected medicines and the Universal Health Care Act of 2019 — continued the access agenda the Act opened, while price surveys kept the record under review.

Challenges and Controversies

The Record on Prices and Availability

The most debated question is whether the Act delivered cheaper medicines. A 2020 cross-sectional survey following the WHO/Health Action International methodology — 50 medicines for diabetes, hypercholesterolemia and hypertension, collected in August 2019 from 36 public and 42 private outlets in six regions — found mean availability of originator brands at only 1.3 percent in public and 34.7 percent in private outlets (lowest-priced generics: 25.0 and 35.4 percent), originator-brand treatments generally unaffordable for a lowest-paid unskilled worker (gliclazide excepted) even with the 12 percent VAT exemption, and generics generally affordable; the authors concluded that “a review of policies and regulations should be initiated for a better access to medicines in the Philippines.” (PubMed — Lambojon et al. 2020)

Comparative Price Performance

A 2026 cross-country comparison in BMC Medicine of 68 medicines found the Philippines with the highest median price ratio of the countries studied — 1.86 against international reference prices, versus 0.88 in China, 0.97 in Thailand and 1.69 in Indonesia — with 67.8 percent of Philippine medicines above the reference price and one defined daily dose requiring a median 14.0 percent of a day’s wage against 3.6 to 5.1 percent elsewhere; the authors urged regional pooled procurement and stronger price transparency. (PubMed — Li et al. 2026)

Due-Process Objections to the Injunction Bars

The provisions that no court except the Supreme Court may restrain government use, compulsory licenses, or presidential price orders — and that appeals do not stay DOH orders — were defended by lawmakers as necessary to prevent litigation from nullifying the Act, and attacked by industry and due-process commentators as concentrating remedies in one tribunal and removing the ordinary interlocutory safeguards of administrative law.

Industry Resistance and the Voluntary-Price Compromise

EO 821’s own text records the compromise: consultations moved many drugs off the compulsory maximum-price list into voluntary reductions — sixteen at fifty percent or more, twenty-two at about ten to fifty percent — a settlement pharmaceutical companies preferred to binding caps but which left the price architecture dependent on executive willingness to act again under Section 17.